Anti-Calcitonin Gene-Related Peptide Monoclonal Antibodies: Adverse Effects. What Do We Really Know? A Literature Review

Anti-Calcitonin Gene-Related Peptide Monoclonal Antibodies: Adverse Effects. What Do We Really Know? A Literature Review

Migraine is a chronic and disabling disorder affecting >1 billion individuals worldwide. Current treatments for the prevention of migraine include antihypertensives, antiepileptics, and antidepressants, and all share limited tolerability and adherence, highlighting the need for the development o...

Full description

Bibliographic Details
Main Authors:	Theodoros Mavridis, Chrysa Koniari, Nikolaos Fakas, Dimos D. Mitsikostas
Format:	Article
Language:	English
Published:	European Medical Journal 2019-01-01
Series:	European Medical Journal Innovations
Subjects:	adverse events (ae) calcitonin gene-related peptide (cgrp) eptinezumab erenumab fremanezumab galcanezumab headache migraine monoclonal antibodies (mab)
Online Access:	https://www.emjreviews.com/innovations/article/anti-calcitonin-gene-related-peptide-monoclonal-antibodies-adverse-effects-what-do-we-really-know-a-literature-review/

Similar Items

Monoclonal Antibodies Targeting CGRP: From Clinical Studies to Real-World Evidence—What Do We Know So Far?
by: Theodoros Mavridis, et al.
Published: (2021-07-01)

Comparison of Treatment Patterns in Patients with Migraine Initiating Calcitonin Gene-Related Peptide Monoclonal Antibodies: A Retrospective Real-World US Study
by: Varnado OJ, et al.
Published: (2024-01-01)

Advances in CGRP monoclonal antibodies as migraine therapy: A narrative review
by: Suruchi Aditya, et al.
Published: (2023-01-01)

Croatian guidelines for specific preventive treatment of migraine with monoclonal antibodies targeting calcitonin gene-related peptide (CGRP) (eptinezumab, fremanezumab, and galcanezumab) or the CGRP receptor (erenumab)
by: Davor Jančuljak, et al.
Published: (2024-01-01)

Monoclonal Antibodies against Calcitonin Gene-Related Peptide for Migraine Prophylaxis: A Systematic Review of Real-World Data
by: Antun R. Pavelic, et al.
Published: (2022-12-01)

Improvement of comorbid anxiety and depression in patients with migraine treated with injectable preventive calcitonin gene-related peptide antagonists: Review of clinical evidence
by: Abubker Omaer, et al.
Published: (2024-04-01)

Monoclonal antibodies for chronic migraine and medication overuse headache: A real-world study
by: Abouch V. Krymchantowski, et al.
Published: (2023-03-01)

A case report of a chronic migraine patient treated with three different anti-CGRP monoclonal antibodies: which parameters better represent the efficacy?
by: Sena Uzun, et al.
Published: (2023-05-01)

Real-world effectiveness of Anti-CGRP monoclonal antibodies compared to OnabotulinumtoxinA (RAMO) in chronic migraine: a retrospective, observational, multicenter, cohort study
by: Licia Grazzi, et al.
Published: (2024-02-01)

Safety and Tolerability of Combining CGRP Monoclonal Antibodies with Gepants in Patients with Migraine: A Retrospective Study
by: Taoufik Alsaadi, et al.
Published: (2024-02-01)

Are indirect comparisons for treatments in migraine necessitas? Many inevitable challenges to overcome
by: Christina Deligianni, et al.
Published: (2023-06-01)

Persistence to anti-CGRP monoclonal antibodies and onabotulinumtoxinA among patients with migraine: a retrospective cohort study
by: Larry Charleston, et al.
Published: (2023-08-01)

Anti-CGRP monoclonal antibodies in the treatment of migraine in women: impact on menstrual relared migraine and algodysmenorrhea
by: Anna V. Berdnikova, et al.
Published: (2023-10-01)

European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention
by: Simona Sacco, et al.
Published: (2019-01-01)

Reducing the Impact of Headache and Allodynia Score in Chronic Migraine: An Exploratory Analysis from the Real-World Effectiveness of Anti-CGRP Monoclonal Antibodies Compared to Onabotulinum Toxin A (RAMO) Study
by: Danilo Antonio Montisano, et al.
Published: (2024-04-01)

Persistent effectiveness of CGRP antibody therapy in migraine and comorbid medication overuse or medication overuse headache - a retrospective real-world analysis
by: Armin Scheffler, et al.
Published: (2024-07-01)

Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review
by: Hugo Sevivas, et al.
Published: (2022-06-01)

Real-life experiences with galcanezumab and predictors for treatment response in Turkey
by: Pınar Yalinay Dikmen, et al.
Published: (2023-11-01)

The Management of High-Frequency Episodic and Chronic Migraines with Calcitonin Gene-Related Peptide Monoclonal Antibody
by: Larisa A. Dobrynina, et al.
Published: (2023-06-01)

Commentary: Constipation caused by anti-calcitonin gene-related peptide migraine therapeutics explained by antagonism of calcitonin gene-related peptide’s motor-stimulating and prosecretory function in the intestine
by: Kimberly D. Mackenzie, et al.
Published: (2022-11-01)

Patients’ Experiences During the Long Journey Before Initiating Migraine Prevention with a Calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibody (mAb)
by: Elizabeth Seng, et al.
Published: (2024-09-01)

Predicting response to CGRP-monoclonal antibodies in patients with migraine in Japan: a single-centre retrospective observational study
by: Keiko Ihara, et al.
Published: (2023-03-01)

Fremanezumab and Non-High-Dose Galcanezumab for Comorbid Cluster Headache in Patients with Migraine: Three Cases
by: Kenta Kashiwagi, et al.
Published: (2023-02-01)

Cerebral Blood Flow and Other Predictors of Responsiveness to Erenumab and Fremanezumab in Migraine—A Real-Life Study
by: Magdalena Nowaczewska, et al.
Published: (2022-05-01)

Combination of anti-CGRP/CGRP-R mAbs with onabotulinumtoxin A as a novel therapeutic approach for refractory chronic migraine: a retrospective study of real-world clinical evidence and a protocol for a double-blind, randomized clinical trial to establish the efficacy and safety
by: M. T. Corasaniti, et al.
Published: (2023-12-01)

Efficacy of erenumab and factors predicting response after 3 months in treatment resistant chronic migraine: a clinical service evaluation
by: Michael Lowe, et al.
Published: (2022-07-01)

The effect and safety of monoclonal antibodies to calcitonin gene-related peptide and its receptor on migraine: a systematic review and meta-analysis
by: Min Hou, et al.
Published: (2017-04-01)

A systematic review of economic evaluations of pharmacological treatments for adults with chronic migraine
by: Saval Khanal, et al.
Published: (2022-09-01)

Glycerol Trinitrate Acts Downstream of Calcitonin Gene-Related Peptide in Trigeminal Nociception—Evidence from Rodent Experiments with Anti-CGRP Antibody Fremanezumab
by: Nicola Benedicter, et al.
Published: (2024-03-01)

Six-month therapy of CGRP monoclonal antibodies in real-world clinical practice: an interim analysis of efficacy and safety data
by: N. V. Vashchenko, et al.
Published: (2022-01-01)

A retrospective analysis of migraine prophylaxis with anti-CGRP monoclonal antibodies at the hospital of Lithuanian University of Health Sciences Kaunas Clinics
by: V. Karpavičiūtė, et al.
Published: (2023-10-01)

Erenumab efficacy predictors for chronic migraine
by: Nina V. Vashchenko
Published: (2022-02-01)

Rapid resolution of migraine symptoms after initiating the preventive treatment eptinezumab during a migraine attack: results from the randomized RELIEF trial
by: Jessica Ailani, et al.
Published: (2022-06-01)

The Role of Galcanezumab in Migraine Prevention: Existing Data and Future Directions
by: Panagiotis Gklinos, et al.
Published: (2021-03-01)

Real-world long-term efficacy and safety of erenumab in adults with chronic migraine: a 52-week, single-center, prospective, observational study
by: Christopher Kjaer Cullum, et al.
Published: (2022-06-01)

Long-term effectiveness and tolerability of galcanezumab in patients with migraine excluded from clinical trials: real world evidence of 1055 patients with 1 year follow-up from the Galca-Only registry
by: Victor Obach, et al.
Published: (2023-11-01)

Galcanezumab effect on “whole pain burden” and multidimensional outcomes in migraine patients with previous unsuccessful treatments: a real-world experience
by: Marcello Silvestro, et al.
Published: (2022-06-01)

Review of Tolerability of Fremanezumab for Episodic and Chronic Migraine
by: Root S, et al.
Published: (2023-02-01)

Two-year effectiveness of erenumab in resistant chronic migraine: a prospective real-world analysis
by: Anna P. Andreou, et al.
Published: (2022-11-01)

A prospective real-world analysis of erenumab in refractory chronic migraine
by: Giorgio Lambru, et al.
Published: (2020-06-01)